idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instanz:
Teilen: 
16.08.2024 14:53

Research at the Paul-Ehrlich-Institut: Findings on Natural Anticoagulants in Treatment of COVID-19

Dr. Susanne Stöcker Medien - und Öffentlichkeitsarbeit
Paul-Ehrlich-Institut - Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel

    The treatment of patients with severe COVID-19 following SARS-CoV-2 infection remains difficult. Severe inflammatory reactions and thrombotic complications (blood clots) in particular can be life-threatening. Classic anticoagulants such as heparin often cannot prevent these complications. An evaluation of literature data shows that natural anticoagulants, known as plasma protease inhibitors, are important in the regulation of out-of-control inflammatory and coagulation processes and should be reviewed for their therapeutic benefits. The journal Biologicals reports on the results online ahead of print.

    There is still an urgent need for effective therapeutics for the treatment of severe COVID-19. One approach that has been discussed is passive immunisation via transfusion of COVID-19 convalescent plasma (CCP). Despite intensive studies, no clear evidence for the efficacy of CCP has been provided thus far, which could be due to differences in study parameters. However, a new study showed mortality decreased significantly after administration of CCP with a high antibody titre within five days of the start of invasive ventilation. Questions still remain about the effectiveness of CCP and manufactured COVID-19 hyperimmune globulin (CHIG). Other recent studies have so far found little to no effect on total mortality.

    Professor Rainer Seitz was a clinician at the University Hospital of Marburg and head of the Haematology and Transfusion Medicine Division at the Paul-Ehrlich-Institut. He investigated this topic with two fellow retired colleagues: Professor Lutz Gürtler, former virologist at the Ludwig-Maximilians-Universität München (LMU) and Professor Wolfgang Schramm, former haematologist at LMU. They evaluated the available data on the three natural protease inhibitors antithrombin III (ATIII), α1-antitrypsin (α1-AT) and α2-macroglobulin (α2-M). Protease inhibitors inhibit the activity of protein-degrading enzymes.

    Protease Inhibitor antithrombin III (ATIII)

    ATIII is available as a plasma-derived concentrate and is found at significantly reduced levels in severe COVID-19 cases. This suggests that ATIII is gradually consumed and its supplementation may be an option, particularly as ATIII has been shown to inhibit the activity of transmembrane serine protease 2 (TMPRSS2). Clinical studies have shown that ATIII plasma levels are significantly lower in individuals who have not survived infection than in survivors.

    Protease Inhibitor α1-antitrypsin (α1-AT)

    Plasma-derived α1-AT is approved to treat adults with severe α1-AT deficiency to slow the progression of emphysema (damage to pulmonary alveoli). Epidemiological studies found a correlation between α1-AT deficiency and COVID-19 pathogenesis.
    α1-AT also inhibits TMPRSS2 activity and thus could be therapeutically relevant.

    Protease Inhibitor α2-macroglobulin (α2-M)

    The protease inhibitor α2-M is currently not available as a therapeutic preparation. Clinical data indicate a reduction in α2-M in COVID-19 patients. There are several arguments in favour of further exploring its predictive and therapeutic potential, as it is a versatile facilitator of host defence systems.

    In conclusion, the authors emphasise that they consider intensive research necessary to further explore the promising possibilities of plasma protease inhibitors in COVID-19 therapy. From their point of view, this research could not only improve the prognosis of COVID-19 patients, but also open up new therapeutic fields for other diseases such as sepsis – the most severe form of infection, also known as blood poisoning.


    Originalpublikation:

    Seitz R, Gürtler L, Schramm W (2024): COVID-19: A case for plasma derived natural anticoagulants?.
    Biologicals 87: 101781
    DOI: 10.1016/j.biologicals.2024.101781


    Weitere Informationen:

    https://www.sciencedirect.com/science/article/pii/S1045105624000381?via%3Dihub - Link to the publication
    https://www.pei.de/EN/newsroom/press-releases/year/2024/09-research-anticoagulan... - This press release on the Website of the Paul-Ehrlich-Institut


    Bilder

    Quote with short Conclusion
    Quote with short Conclusion
    Paul-Ehrlich-Institut


    Anhang
    attachment icon Audioquote with short conclusion

    Merkmale dieser Pressemitteilung:
    Journalisten, Wissenschaftler
    Biologie, Medizin
    überregional
    Forschungsergebnisse, Wissenschaftliche Publikationen
    Englisch


     

    Quote with short Conclusion


    Zum Download

    x

    Hilfe

    Die Suche / Erweiterte Suche im idw-Archiv
    Verknüpfungen

    Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.

    Klammern

    Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).

    Wortgruppen

    Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.

    Auswahlkriterien

    Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).

    Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).